المؤلفون: N. V. Trushenko, B. B. Lavginova, G. S. Nuralieva, S. N. Avdeev, Н. В. Трушенко, Б. Б. Лавгинова, Г. С. Нуралиева, С. Н. Авдеев

المصدر: Meditsinskiy sovet = Medical Council; № 20 (2023); 10-17 ; Медицинский Совет; № 20 (2023); 10-17 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: длительнодействующие антагонисты мускариновых рецепторов, combination inhaler, inhaled corticosteroids, long-acting beta-agonists, long-acting anticholinergics, эозинофилия, комбинированные ингаляционные средства, ингаляционные глюкокортикостероиды, длительнодействующие бета2-агонисты

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7877/6992; Авдеев СН, Айсанов ЗР, Ардашева ТВ, Белевский АС, Демко ИВ, Зайцев АА и др. Хроническая обструктивная болезнь легких: клинические рекомендации. 2023. 100 с. Режим доступа: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdf.; Авдеев СН, Айсанов ЗР, Архипов ВВ, Белевский АС, Визель АА, Демко ИВ и др. Назначение/отмена ингаляционных глюкокортикостероидов у больных хронической обструктивной болезнью легких как терапевтический континуум в реальной клинической практике. Пульмонология. 2023;33(1):109–118. https://doi.org/10.18093/0869-0189-202333-1-109-118.; Авдеев СН, Невзорова ВА, Куделя ЛМ, Кондрашова НМ, Суханова ГИ, Киняйкин МФ и др. Вопросы тройной терапии в лечении хронической обструктивной болезни легких. Комментарии к алгоритму. Резолюция Совета экспертов от 13.06.18 (Владивосток). Пульмонология. 2019;29(3):365–374. https://doi.org/10.18093/0869-0189-2019-29-3-365-374.; Calzetta L, Matera MG, Rogliani P, Cazzola M. The role of triple therapy in the management of COPD. Expert Rev Clin Pharmacol. 2020;13(8):865–874. https://doi.org/10.1080/17512433.2020.1787830.; Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6(10):747–758. https://doi.org/10.1016/S2213-2600(18)30327-8.; Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Trivedi R, Jenkins M et al. Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021;185:106509. https://doi.org/10.1016/j.rmed.2021.106509.; Ishiura Y, Fujimura M, Ohkura N, Hara J, Kasahara K, Ishii N et al. Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap. Int J Chron Obstruct Pulmon Dis. 2020;15:269–277. https://doi.org/10.2147/COPD.S231004.; Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-VerySevere COPD. N Engl J Med. 2020;383(1):35–48. https://doi.org/10.1056/NEJMoa1916046.; Singh D, Rabe KF, Martinez FJ, Krüll M, Jenkins M, Patel M, Dorinsky P. Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. Respir Med. 2022;197:106857. https://doi.org/10.1016/j.rmed.2022.106857.; Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C et al. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/ Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med. 2021;203(5):553–564. https://doi.org/10.1164/rccm.202006-2618OC.; Kolsum U, Damera G, Pham TH, Southworth T, Mason S, Karur P et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017;140(4):1181–1184. https://doi.org/10.1016/j.jaci.2017.04.027.; Hasegawa K, Camargo CAJr. Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD. Respirology. 2016;21(4):761–764. https://doi.org/10.1111/resp.12724.; Landis S, Suruki R, Maskell J, Bonar K, Hilton E, Compton C. Demographic and Clinical Characteristics of COPD Patients at Different Blood Eosinophil Levels in the UK Clinical Practice Research Datalink. COPD. 2018;15(2):177–184. https://doi.org/10.1080/15412555.2018.1441275.; Bacci E, Cianchetti S, Bartoli M, Dente FL, Di Franco A, Vagaggini B, Paggiaro P. Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest. 2006;129(3):565–572. https://doi.org/10.1378/chest.129.3.565.; Pizzichini E, Pizzichini MM, Gibson P, Parameswaran K, Gleich GJ, Berman L et al. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998;158(5):1511–1517. https://doi.org/10.1164/ajrccm.158.5.9804028.; Park HY, Lee H, Koh WJ, Kim S, Jeong I, Koo HK et al. Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. Int J Chron Obstruct Pulmon Dis. 2015;11:23–30. https://doi.org/10.2147/COPD.S94797.; Авдеев СН, Трушенко НВ, Мержоева ЗМ, Иванова МС, Кусраева ЭВ. Эозинофильное воспаление при хронической обструктивной болезни легких. Терапевтический архив. 2019;91(10):144–152. https://doi.org/10.26442/00403660.2019.10.000426.; Лещенко ИВ, Мещерякова АС. Современные возможности терапии ингаляционными глюкокортикостероидами пациентов с хронической обструктивной болезнью легких. Пульмонология. 2021;31(1):75–87. https://doi.org/10.18093/0869-0189-2021-31-1-75-87.; Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M et al. Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS. Int J Chron Obstruct Pulmon Dis. 2022;17:3061–3073. https://doi.org/10.2147/COPD.S374670.; Muro S, Sugiura H, Darken P, Dorinsky P. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts. Respir Res. 2021;22(1):187. https://doi.org/10.1186/s12931-021-01773-1.; Marsh SE, Travers J, Weatherall M, Williams MV, Aldington S, Shirtcliffe PM et al. Proportional classification of COPD phenotypes. Thorax. 2008;63(9):761–767. https://doi.org/10.1136/thx.2007.089193.; Shaya FT, Dongyi D, Akazawa MO, Blanchette CM, Wang J, Mapel DW et al. Burden of concomitant asthma and COPD in a Medicaid population. Chest. 2008;134(1):14–19. https://doi.org/10.1378/chest.07-2317.; Hardin M, Silverman EK, Barr RG, Hansel NN, Schroeder JD, Make BJ et al. The clinical features of the overlap between COPD and asthma. Respir Res. 2011;12(1):127. https://doi.org/10.1186/1465-9921-12-127.; Park SY, Kim S, Kim JH, Kim SH, Lee T, Yoon SY et al. A Randomized, Noninferiority Trial Comparing ICS + LABA with ICS + LABA + LAMA in Asthma-COPD Overlap (ACO) Treatment: The ACO Treatment with Optimal Medications (ATOMIC) Study. J Allergy Clin Immunol Pract. 2021;9(3):1304–1311. https://doi.org/10.1016/j.jaip.2020.09.066.; Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med. 2018;378(18):1671–1680. https://doi.org/10.1056/NEJMoa1713901.; Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet. 2018;391(10125):1076–1084. https://doi.org/10.1016/S0140-6736(18)30206-X.; Izquierdo JL, Cosio BG. The dose of inhaled corticosteroids in patients with COPD: when less is better. Int J Chron Obstruct Pulmon Dis. 2018;13:3539–3547. https://doi.org/10.2147/COPD.S175047.; Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. https://doi.org/10.1136/thorax.57.10.847.; Cazzola M, Rogliani P, Laitano R, Calzetta L, Matera MG. Beyond Dual Bronchodilation – Triple Therapy, When and Why. Int J Chron Obstruct Pulmon Dis. 2022;17:165–180. https://doi.org/10.2147/COPD.S345263.; https://www.med-sovet.pro/jour/article/view/7877

الاتاحة: https://www.med-sovet.pro/jour/article/view/7877
https://doi.org/10.21518/ms2023-382

المؤلفون: Masayuki Hojo, Motoyasu Iikura, Junko Hirashima, Manabu Suzuki, Haruhito Sugiyama

المصدر: Allergology International, Vol 63, Iss 1, Pp 103-111 (2014)

مصطلحات موضوعية: airway inflammation, bronchial asthma, budesonide/formoterol combination inhaler, fractional exhaled nitric oxide (FeNO), salmeterol/fluticasone combination inhaler, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S1323893015300149; https://doaj.org/toc/1323-8930

URL الوصول: https://doaj.org/article/cb47cf1db6de4d68b4ec971d4256327f

المؤلفون: Masayuki Hojo, Tomonori Mizutani, Motoyasu Iikura, Satoshi Hirano, Nobuyuki Kobayashi, Haruhito Sugiyama

المصدر: Allergology International, Vol 62, Iss 1, Pp 91-98 (2013)

مصطلحات موضوعية: asthma, Asthma Control Test, budesonide/formoterol combination inhaler, fractional exhaled nitric oxide (FeNO), step down, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S132389301530112X; https://doaj.org/toc/1323-8930

URL الوصول: https://doaj.org/article/a6bbd3f11c224bfcbfeb74172834973b

المؤلفون: Atsuhito Sugiyama, Koichiro Kudo, Masayuki Hojo, Motoyasu Iikura, Nobuyuki Kobayashi, Tomonori Mizutani, 小林 信之, 工藤 宏一郎, 放生 雅章, 杉山 温人, 水谷 友紀, 飯倉 元保

المصدر: アレルギー / Japanese Journal of Allergology. 2011, 60(5):575

المؤلفون: Haruhito Sugiyama, Motoyasu Iikura, Masayuki Hojo, Manabu Suzuki, Junko Hirashima

المصدر: Allergology International, Vol 63, Iss 1, Pp 103-111 (2014)

مصطلحات موضوعية: lcsh:Immunologic diseases. Allergy, Budesonide, Adult, Male, animal structures, airway inflammation, Nitric Oxide, Medication Adherence, Young Adult, fractional exhaled nitric oxide (FeNO), Maintenance therapy, Adrenal Cortex Hormones, Formoterol Fumarate, medicine, Immunology and Allergy, Humans, Albuterol, Adrenergic beta-2 Receptor Agonists, Fluticasone, Aged, Fluticasone-Salmeterol Drug Combination, salmeterol/fluticasone combination inhaler, business.industry, Inhaler, Nebulizers and Vaporizers, budesonide/formoterol combination inhaler, General Medicine, Middle Aged, Asthma, respiratory tract diseases, Androstadienes, Drug Combinations, Budesonide/formoterol, Ethanolamines, Exhalation, Anesthesia, Case-Control Studies, Female, bronchial asthma, Salmeterol, Formoterol, lcsh:RC581-607, business, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae9c78ae476f07e761a2ae9e2066b644
https://pubmed.ncbi.nlm.nih.gov/24569153

المؤلفون: Singh, Dave, Piccinno, Annalisa, Borrill, Zoe, Poli, Gianluigi, Acerbi, Daniela, Meuleners, Luc, Woodcock, Ashley

المصدر: Singh , D , Piccinno , A , Borrill , Z , Poli , G , Acerbi , D , Meuleners , L & Woodcock , A 2008 , ' Tolerability of high cumulative doses of the HFA modulite beclomethasone dipropionate/formoterol combination inhaler in asthmatic patients ' , Pulmonary Pharmacology and Therapeutics , vol. 21 , no. 3 , pp. 551-557 . https://doi.org/10.1016/j.pupt.2008.01.001

مصطلحات موضوعية: Asthma, Beclomethasone, Combination inhaler, Formoterol, Modulite, Tolerability

الاتاحة: https://research.manchester.ac.uk/en/publications/a1799bb8-64e4-406b-953f-aca86a680103
https://doi.org/10.1016/j.pupt.2008.01.001